Drugs / Custodiol-N
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07381530 | Dec 2024 → Dec 2026 | congenital heart malformation | Dr. F. Köhler Chemie GmbH | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT06032195 | Aug 2023 → Jan 2027 expected | — | Dr. F. Köhler Chemie GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT01444235 | Mar 2011 → May 2012 | coronary artery disorder | Dr. F. Köhler Chemie GmbH | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02869022 | Jul 2016 → Sep 2019 | heart failure | Dr. F. Köhler Chemie GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02098772 | May 2014 → Nov 2018 | aortic valve disorder, coronary artery disorder | Dr. F. Köhler Chemie GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Custodiol-N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06032195 ↗ |
| Route | Other | “will be infused antegrade into the root of the aorta” NCT01444235 ↗ |